Tonrol Biopharmaceutical

Tonrol Biopharmaceutical is a clinical-stage Chinese biotechnology company focused on the development of innovative and biosimilar therapeutic antibodies for autoimmune diseases, inflammatory conditions, and oncology. The company's lead programs include TR001, an IL-17A inhibitor currently in late-stage clinical trials for plaque psoriasis and ankylosing spondylitis. Tonrol maintains a robust pipeline of monoclonal and bispecific antibodies targeting key inflammatory pathways such as IL-4R, IL-5, and IL-33. Headquartered in Hefei, China, the company operates integrated research, development, and large-scale GMP manufacturing facilities to support its transition toward commercialization. Tonrol aims to provide high-quality, affordable biological therapies to patients globally through internal innovation and strategic collaborations.